PRQR - プロキュ―ア―ル・セラピュ―ティクス (ProQR Therapeutics N.V.)

PRQRのニュース

   Analysts Predict A Surge In ProQR Therapeutics N.V. (NASDAQ: PRQR)?  2022/06/25 11:00:00 Stocks Register
ProQR Therapeutics N.V. (NASDAQ:PRQR) shares, rose in value on Friday, 06/24/22, with the stock price down by -16.27% to the previous day’s close as strong demand from buyers drove the stock to $0.68. Actively observing the price movement in the last trading, the stock closed the session at $0.81, falling within a range of $0.68 … Analysts Predict A Surge In ProQR Therapeutics N.V. (NASDAQ: PRQR)? Read More »
   ProQR to Present its Axiomer RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022  2022/05/09 11:00:00 Wallstreet:Online
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference, or TIDES USA, that is being held May 9-12, 2022 in Boston, MA, U.S. ProQR presentation
   Expert Ratings for ProQR Therapeutics  2022/05/06 14:04:32 Benzinga
Within the last quarter, ProQR Therapeutics (NASDAQ: PRQR ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 1 0 0 0 In the last 3 months, 6 analysts have offered 12-month price targets for ProQR Therapeutics. The company has an average price target of $4.92 with a high of $8.00 and a low of $2.00. Below is a summary of how these 6 analysts rated ProQR Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the … Full story available on Benzinga.com
   ProQR Announces First Quarter 2022 Operating and Financial Results  2022/05/05 20:30:00 GlobeNewswire
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today reported its financial and operating results for the first quarter ended March 31, 2022, and provided a business update.
   ProQR Therapeutics (PRQR) Investor Presentation - Slideshow  2022/04/29 17:50:54 Seeking Alpha
The following slide deck was published by ProQR Therapeutics N.V.
   ProQR Therapeutics (PRQR) Investor Presentation - Slideshow  2022/04/29 17:50:54 Seeking Alpha
The following slide deck was published by ProQR Therapeutics N.V.
   Enrapturing stocks: Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS 7.84%), ProQR Therapeutics N.V. (NASDAQ:PRQR -0.39%)  2022/04/15 18:54:16 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Enrapturing stocks: Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS 7.84%), ProQR Therapeutics N.V. (NASDAQ:PRQR -0.39%) appeared first on Stocks Equity .
   ProQR Therapeutics Pulls Plug On Inherited Retinal Disease Programs, Cuts 30% Workforce  2022/04/13 13:49:29 Benzinga
ProQR Therapeutics N.V. (NASDAQ: PRQR ) has decided to prioritize the development of genetic eye disease candidates and the Axiomer RNA base-editing technology platform. The Company will suspend the development of QR-1123 for autosomal dominant retinitis pigmentosa, QR-504a for Fuchs endothelial corneal dystrophy, and all other Inherited Retinal diseases (IRD)-related research activities. ProQR will implement restructuring initiatives, including a 30% workforce reduction and the departure of Chief Scientific Officer Naveed Shams, expected to be effective in Q2. ProQR … Full story available on Benzinga.com
   Glistering Stock: ProQR Therapeutics N.V. (NASDAQ:PRQR), Enservco Corporation (AMEX:ENSV)  2022/03/08 04:20:09 Stock Equity
ProQR Therapeutics N.V. (NASDAQ:PRQR) with the stream of 3.15% also noticed, India Enservco Corporation (AMEX:ENSV) encountered a rapid change of 85.19% in the last hour of Monday’s trading session. ProQR … The post Glistering Stock: ProQR Therapeutics N.V. (NASDAQ:PRQR), Enservco Corporation (AMEX:ENSV) appeared first on Stocks Equity .
   Is ProQR Therapeutics N.V. (NASDAQ: PRQR) Still A Loss Stock Despite Being Down -85.02% YTD?  2022/02/18 16:30:00 Marketing Sentinel
During the last session, ProQR Therapeutics N.V. (NASDAQ:PRQR)’s traded shares were 3.38 million, with the beta value of the company hitting 0.57. At the end of the trading day, the stock’s price was $1.20, reflecting an intraday loss of -1.64% or -$0.02. The 52-week high for the PRQR share is $9.46, that puts it down … Is ProQR Therapeutics N.V. (NASDAQ: PRQR) Still A Loss Stock Despite Being Down -85.02% YTD? Read More »
   Is ProQR Therapeutics N.V. (NASDAQ: PRQR) A Stock A New Investor Should Consider Now?  2021/12/18 12:30:00 Stocks Register
ProQR Therapeutics N.V. (NASDAQ:PRQR) shares, rose in value on Friday, 12/17/21, with the stock price up by 6.14% to the previous days close as strong demand from buyers drove the stock to $7.43. Actively observing the price movement in the last trading, the stock closed the session at $7.00, falling within a range of $6.75 Is ProQR Therapeutics N.V. (NASDAQ: PRQR) A Stock A New Investor Should Consider Now? Read More »
   ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa  2021/12/16 12:00:00 Intrado Digital Media
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the first patients dosed in Phase 2/3 Sirius and Celeste clinical trials of investigational RNA therapy QR-421a for people with USH2A mediated retinitis pigmentosa (RP) and Usher syndrome.
   ProQR Therapeutics N.V. (PRQR) Probability Sentiment  2021/12/11 22:04:16 GEO Investing
Proqr Therapeutics N.v. (NASDAQ:PRQR) Probability Sentiment SUMMARY In many diseases, discovering the key gene or protein target to treat remains elusive. Not so with the rare eye disease CEP290-mediated Leber congenital amaurosis (LCA10). People with CEP290-mediated LCA10 suffer vision loss because of a specific mutation in the CEP290 gene. The []
   Northern Trust Corp Has $91,000 Holdings in ProQR Therapeutics (NASDAQ:PRQR)  2021/12/07 09:08:49 Dakota Financial News
Northern Trust Corp lowered its position in shares of ProQR Therapeutics (NASDAQ:PRQR) by 24.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,481 shares of the biopharmaceutical companys stock after selling 4,432 shares during the quarter. Northern Trust Corps holdings in []
   ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of Buy by Analysts  2021/11/30 12:48:41 Dakota Financial News
Shares of ProQR Therapeutics (NASDAQ:PRQR) have been given an average rating of Buy by the nine research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokerages []

calendar